Расширенный поиск

Новые возможности применения фторхинолонов в пульмонологии

Полный текст:

Об авторах

Л. С. Страчунский
НИИ антимикробной химиотерапии, Смоленская государственная медицинская академия

А. В. Веселов
НИИ антимикробной химиотерапии, Смоленская государственная медицинская академия

В. А. Кречиков
НИИ антимикробной химиотерапии, Смоленская государственная медицинская академия

Список литературы

1. Hooper D., Rubinstein Е., eds. Quinolone antimicrobial agents. 3-rd ed. AMS Press; 2003.

2. Brueggemann A., Coffman S., Rhomberg P. et al. Fluoroquinolone resistance in streptococcus pneumoniae in the United States since 1994-1995. Antimicrob. Agents Chemother. 2002; 46: 680-688.

3. Song J.H., Jung S.I., Ко K.S. et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 2004; 48: 2101-2107.

4. Ho P., Tse W., Tsang K. et al. Risk factors for acquisition of lev-ofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. 2001; 341: 1546-1548.

5. Niederman AL, Mandell L., Anzueto A. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.

6. Stratchounski L.S., Kozlov R.S., Sivaja O.V., Poupard J.A. Antimicrobial resistance in Russia among Streptococcus pneumoniae causing community-acquired respiratory tract infections: PEHASus-I surveillance program, 2001-2002. In: Proceedings of 41-st Annual meeting of the IDSA, 9-12 October, 2003. San Diego; 2003. Abstr. 207.

7. Stratchounski L.S., Tarasov A.A., Kozlov R.S. et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from adults with acute sinusitis in 3 Russian centers. In: Proceedings of 14-th ECCMID, 1-4 May 2004. Prague; 2004. Abstr. PI 147.

8. Grudinina S.F., Sidorenko S.F., Rezvan S.P. et al. Five year surveillance of Streptococcus pneumoniae resistance in Moscow, Russia. In: Proceedings of 43-rd ICAAC, 14-17 September 2003. Chicago; 2003. Abstr. C2-945.

9. Martynova A.V., Turcutyuicov V.B. Epidemiology of antibiotic-resistant Streptococcus pneumoniae strains in Far East Russia. Int. J. Antimicrob. Agents 2004; 23: 641-643.

10. Nuermberger E., Bishai W. Management of community-acquired pneumonia caused by drug-resistant Streptococcus pneumoniae. In: Gillespie S., ed. Management of multiple drug-resistant infections. Totowfa: Humana Press; 2004. 3-29.

11. Howe R., MacGovan A. Quinolones. In: Cohen G., Powderly W., eds. /nfectious diseases. 2-nd ed. Amsterdam: Elsevier Ltd.; 2004. 1827-1836.

12. Wise R. Maximizing efficacy and reducing the emergence of resistance. J. Antimicrob. Chemother. 2003; 51 (suppl. 1): 37-42.

13. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infectious. Curr. Opin. Infect. Dis. 2001; 14: 165-172.

14. Zhanel G., Walters M., Karlowsky J. et al. Activity of free (unbound) fluoroquinolone serum concentrations versus multi-drug resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model. In: Proceedings of the 40-th ICAAC, 17—20 September 2000. Toronto; 2000. Abstr. A-292.

15. Wright D., Brown G., Peterson AL, Rotschafer J. Application of fluoroquinolones pharmacodynamics. J. Antimicrob. Chemother. 2000; 46: 669-683.

16. Data on file. Bristol-Myers Squibb.

17. Data on file. Oscient Pharmaceuticals.

18. Grohs P., Houssaye S., Aubert A. et al. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci and Enterococcus faecalis compared to those of six other quinolones. Antimicrob. Agents Chemother. 2003; 47: 3542-3547.

19. Perez-Vazquez M., Roman F., Aracil B. et al. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilites. Antimicrob. Agents Chemother. 2003; 47: 3539-3541.

20. Christiansen K.J., Bell J.M., Turnidge J.D., Jones R.N. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob. Agents Chemother. 2004; 48: 2049-2055.

21. Liebetrau A., Rodloff A.C., Behra-Miellet J., Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother. 2003; 47: 3667-3671.

22. Blondeau J.M., Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert. Opin. Pharmacother. 2004; 5: 1117-1152.

23. Appelbaum P.C., Gillespie S.H., Burley C.J., Tillotson G.S. Antimicrobial selection for community-acquired lower respiratory tract infections in 21st century: a review of gemifloxacin. Int. J. Antimicrob. Agents 2004; 23: 533-546.

24. Allen A., Bygate E., Oliver S. et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 2000; 44: 1604-1608.

25. Leophonte P., File T., Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 2004; 98: 708-720.

26. Sethi S., Fogarty C., Fulambarker A. A randomized, doubleblind study comparing 5 days oral gemifloxacin with 7 days oral ievofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697-707.

27. Ball P., Mandell L., Patou G. et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int. J. Antimicrob. Agents 2004; 23: 421-429.

28. Dunbar L., Wunderink R., Habib M. et al. High-dose, short-course ievofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 2003; 37: 752-760.

29. Karlowsky J., Thornsberry C, Critchley I. et al. Susceptibilities to ievofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: Results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. 2003; 47: 1790-1797.

30. Yu V., Greenberg R., Zadeikis N. et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139. "

31. Dunbar L., Khashab M., Kahn J. et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 2004; 20: 555-563.

32. Антипин A.H., Арсенин С.Л., Прилуцкая M.A., Белобородов В.Б. Особенности диагностики и лечения внебольничной пневмонии, вызванной Legionella pneumophila. Рос. мед. вести 2004; (2): 23-31.

33. West AL, Boulanger В., Fogarty С. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 2003; 25: 485-506.

34. Croom К., Goa L. Levofloxacin. A review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-2802.

35. Nightingale C., Grant £., Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 (suppl. 1): 6-14.

36. Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr. Ther. Res. 2003; 64: 646-661.

37. Kahn J. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 (suppl. 3): 32-37.

Для цитирования:

Страчунский Л.С., Веселов А.В., Кречиков В.А. Новые возможности применения фторхинолонов в пульмонологии. Пульмонология. 2004;(6):110-118.

For citation:

Strachunsky L.S., Veselov A.V., Krechikov V.A. New opportunities to use fluoroquinolones in pulmonology. PULMONOLOGIYA. 2004;(6):110-118. (In Russ.)

Просмотров: 6

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)